ASTRAZENNSEAstraZeneca Pharma India Limited· PharmaceuticalsHighNegative
Announced Thu, 4 Jun · 15:42 IST

AstraZeneca Pharma India Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Regulatory & Legal View source PDF

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.4%1-day move
₹8540.00
prior close
₹8454.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+1.0+0.8+0.8-1.4-1.8-2.5-3.8-3.6-0.4-5.4-3.4
Up moveDown movePending
AI summary

AstraZeneca Pharma India Limited has submitted a disclosure to the stock exchange regarding the pendency of litigation(s) or dispute(s), or the outcome of such matters, that could have an impact on the company. This is a routine compliance filing under SEBI's listing obligations, requiring listed companies to keep the exchange informed of material legal proceedings. The specific details of the case(s) — such as the nature of the dispute, the amount involved, or the stage of proceedings — have not been disclosed in the headline. Investors would need to refer to the full filing or the company's annual report for complete information.

Likely market impact

Without specifics on the nature or quantum of the litigation, the immediate impact on shareholders is unclear. Any material legal development could affect stock sentiment, especially if financial penalties or regulatory action are involved.